Title:
線維症を処置するためのセニクリビロック併用療法
Document Type and Number:
Japanese Patent JP2017526713
Kind Code:
A
Abstract:
セニクリビロック（ＣＶＣ）は、Ｃ−Ｃケモカイン受容体５型（ＣＣＲ５）及びＣ−Ｃケモカイン受容体２型（ＣＣＲ２）に結合するリガンドの経口活性アンタゴニストである。ＣＶＣは、ＣＣＲ５へのＲＡＮＴＥＳ、ＭＩＰ−１α、及びＭＩＰ−１βの結合、ならびにＣＣＲ２へのＭＣＰ−１／ＣＣＬ２の結合を遮断する。ＦＸＲアゴニスト、高用量ビタミンＥ（＞４００ｉＵ／ｄ）、ペルオキシソーム増殖因子活性化受容体アルファ（ＰＰＡＲ−α）アゴニスト、ＰＰＡＲ−γアゴニスト、ＰＰＡＲ−δアゴニスト、及び／またはケモカインアンタゴニストと共にＣＶＣを同時投与することを含む、線維症及び関連状態を処置する方法を本明細書において提供する。【選択図】図１
Inventors:
Eric Lefevre
Application Number:
JP2017513634A
Publication Date:
September 14, 2017
Filing Date:
September 11, 2015
Export Citation:
Assignee:
Tobira Therapeutics, Incorporated
International Classes:
A61K31/4178; A61K31/19; A61K31/195; A61K31/355; A61K31/42; A61K31/4439; A61K31/575; A61K45/00; A61K47/12; A61P1/16; A61P3/10; A61P13/12; A61P31/14; A61P31/18; A61P31/20
Domestic Patent References:
| JP6391674B2 | 2018-09-19 | |||
| JP2017509704A | 2017-04-06 |
Foreign References:
| US20070015796A1 | 2007-01-18 |
Other References:
"Tobira therapeutics Presents Data Supporting ANti-Fibrotic Activity of Cenicriviroc in Liver Disease", BUSINESS WIRE, JPN6019018463, 4 November 2013 (2013-11-04), ISSN: 0004379059
AM J PHYSIOL RENAL PHYSIOL, vol. 289, JPN6019018479, 2005, pages 1153 - 1158, ISSN: 0004255991
ENDOCRINOLOGY, vol. 154, no. 5, JPN6019018481, 2013, pages 1794 - 1801, ISSN: 0004379066
日薬理誌, vol. 128, JPN6019018482, 2006, pages 235 - 238, ISSN: 0004379067
"Fumaric Acid Microenvironment Tablet Formulation and Process Development for Crystalline Cenicriviro", MOLECULAR PHARMACEUTICS, vol. 10 (11), JPN6019018483, 2013, pages 4005 - 4015, ISSN: 0004379068
"Anti-fibrotic and anti-inflammatory activity of the dual CCR5 and CCR2 antagonist cenicriviroc in a", THE NATIONAL AIDS TREATMENT ADVOCACY PROJECT HOME PAGE, JPN6019018465, 2 April 2019 (2019-04-02), ISSN: 0004379060
"Anti-fibrotic and anti-inflammatory activity of the dual CCR5 and CCR2 antagonist cenicriviroc in a", ANTIVIRAL THERAPY, vol. 18 (SUPPL. 3), JPN6019018468, 2013, pages 14 - 15, ISSN: 0004379061
"Significant Anti-Fibrotic Activity of Cenicriviroc, A Dual CCR2/CCR5 Antagonist, in a Rat Model of T", HEPATOLOGY, vol. 58 (6), JPN6019018469, 2013, pages 1381 - 1382, ISSN: 0004379062
"Cenicriviroc, an orally active CCR5 antagonist for the potential treatment of HIV infection", CURRENT OPINION IN INVESTIGATIONAL DRUGS (BIOMED CENTRAL), vol. 11 (8), JPN6019018471, 2010, pages 940 - 950, ISSN: 0004379063
"TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favora", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 49 (11), JPN6019018473, 2005, pages 4584 - 4591, ISSN: 0004379064
"Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-depen", CLIN CHIM ACTA, vol. 381 (2), JPN6019018475, 2007, pages 107 - 113, ISSN: 0004379065
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 291, no. 1, JPN6019018477, 2002, pages 55 - 61, ISSN: 0004255990
AM J PHYSIOL RENAL PHYSIOL, vol. 289, JPN6019018479, 2005, pages 1153 - 1158, ISSN: 0004255991
ENDOCRINOLOGY, vol. 154, no. 5, JPN6019018481, 2013, pages 1794 - 1801, ISSN: 0004379066
日薬理誌, vol. 128, JPN6019018482, 2006, pages 235 - 238, ISSN: 0004379067
"Fumaric Acid Microenvironment Tablet Formulation and Process Development for Crystalline Cenicriviro", MOLECULAR PHARMACEUTICS, vol. 10 (11), JPN6019018483, 2013, pages 4005 - 4015, ISSN: 0004379068
"Anti-fibrotic and anti-inflammatory activity of the dual CCR5 and CCR2 antagonist cenicriviroc in a", THE NATIONAL AIDS TREATMENT ADVOCACY PROJECT HOME PAGE, JPN6019018465, 2 April 2019 (2019-04-02), ISSN: 0004379060
"Anti-fibrotic and anti-inflammatory activity of the dual CCR5 and CCR2 antagonist cenicriviroc in a", ANTIVIRAL THERAPY, vol. 18 (SUPPL. 3), JPN6019018468, 2013, pages 14 - 15, ISSN: 0004379061
"Significant Anti-Fibrotic Activity of Cenicriviroc, A Dual CCR2/CCR5 Antagonist, in a Rat Model of T", HEPATOLOGY, vol. 58 (6), JPN6019018469, 2013, pages 1381 - 1382, ISSN: 0004379062
"Cenicriviroc, an orally active CCR5 antagonist for the potential treatment of HIV infection", CURRENT OPINION IN INVESTIGATIONAL DRUGS (BIOMED CENTRAL), vol. 11 (8), JPN6019018471, 2010, pages 940 - 950, ISSN: 0004379063
"TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favora", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 49 (11), JPN6019018473, 2005, pages 4584 - 4591, ISSN: 0004379064
"Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-depen", CLIN CHIM ACTA, vol. 381 (2), JPN6019018475, 2007, pages 107 - 113, ISSN: 0004379065
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 291, no. 1, JPN6019018477, 2002, pages 55 - 61, ISSN: 0004255990
Attorney, Agent or Firm:
Hidesaku Yamamoto
Natsuki Morishita
Takatoshi Iida
Daisuke Ishikawa
Kensaku Yamamoto
Natsuki Morishita
Takatoshi Iida
Daisuke Ishikawa
Kensaku Yamamoto